Key Points
- Insider sale: Joshua Foukas sold 4,461 USANA (NYSE:USNA) shares on Feb. 20 at an average price of $21.34 for a total of $95,197.74, disclosed in an SEC filing.
- Q4 results beat: USANA reported $0.60 EPS versus $0.41 expected and $226.2M in revenue (roughly in line), with analysts projecting $2.45 EPS for the year; the company reported a net margin of 1.16% and ROE of 6.75%.
- Cautious market view: the stock has a market cap of ~$397M and a 52-week range of $18.48–$38.32, and MarketBeat shows a consensus rating of "Reduce" with a $36 price target despite some recent analyst upgrades and institutional inflows.
USANA Health Sciences, Inc. (NYSE:USNA - Get Free Report) insider Joshua Foukas sold 4,461 shares of USANA Health Sciences stock in a transaction that occurred on Friday, February 20th. The shares were sold at an average price of $21.34, for a total transaction of $95,197.74. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.
USANA Health Sciences Stock Up 0.3%
USNA opened at $21.73 on Tuesday. The stock has a market cap of $397.22 million, a PE ratio of 39.51, a P/E/G ratio of 0.90 and a beta of 0.67. USANA Health Sciences, Inc. has a 52 week low of $18.48 and a 52 week high of $38.32. The business's fifty day simple moving average is $20.73 and its 200 day simple moving average is $23.40.
USANA Health Sciences (NYSE:USNA - Get Free Report) last posted its quarterly earnings results on Tuesday, February 17th. The company reported $0.60 EPS for the quarter, topping the consensus estimate of $0.41 by $0.19. The firm had revenue of $226.20 million for the quarter, compared to the consensus estimate of $225.96 million. USANA Health Sciences had a net margin of 1.16% and a return on equity of 6.75%. As a group, equities analysts anticipate that USANA Health Sciences, Inc. will post 2.45 earnings per share for the current year.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently made changes to their positions in the company. State of Alaska Department of Revenue grew its stake in USANA Health Sciences by 8.5% in the fourth quarter. State of Alaska Department of Revenue now owns 6,666 shares of the company's stock worth $130,000 after purchasing an additional 525 shares during the period. Russell Investments Group Ltd. boosted its holdings in shares of USANA Health Sciences by 4.6% during the 4th quarter. Russell Investments Group Ltd. now owns 12,431 shares of the company's stock valued at $244,000 after buying an additional 542 shares in the last quarter. Creative Planning grew its position in shares of USANA Health Sciences by 3.2% in the 2nd quarter. Creative Planning now owns 20,051 shares of the company's stock worth $612,000 after buying an additional 613 shares during the period. Quantbot Technologies LP grew its position in shares of USANA Health Sciences by 19.5% in the 2nd quarter. Quantbot Technologies LP now owns 3,957 shares of the company's stock worth $121,000 after buying an additional 646 shares during the period. Finally, Intech Investment Management LLC increased its stake in shares of USANA Health Sciences by 13.5% in the 3rd quarter. Intech Investment Management LLC now owns 7,722 shares of the company's stock worth $213,000 after acquiring an additional 918 shares in the last quarter. Hedge funds and other institutional investors own 54.25% of the company's stock.
Analyst Ratings Changes
A number of analysts have recently weighed in on the stock. Zacks Research upgraded shares of USANA Health Sciences from a "strong sell" rating to a "hold" rating in a report on Monday, February 16th. Weiss Ratings reaffirmed a "sell (d)" rating on shares of USANA Health Sciences in a research report on Monday, December 29th. Finally, Wall Street Zen upgraded USANA Health Sciences from a "hold" rating to a "buy" rating in a research report on Saturday. Two equities research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Reduce" and a consensus price target of $36.00.
Get Our Latest Stock Report on USNA
USANA Health Sciences Company Profile
(
Get Free Report)
USANA Health Sciences, Inc is a Utah‐based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company's portfolio includes vitamins, minerals, dietary supplements, weight‐management products and skin‐care formulations. USANA's products are formulated in its own laboratories to meet pharmaceutical‐grade standards, and the company has invested heavily in research and development and quality control to support its offerings.
Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
